<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802980</url>
  </required_header>
  <id_info>
    <org_study_id>HB002.1T-02</org_study_id>
    <nct_id>NCT04802980</nct_id>
  </id_info>
  <brief_title>A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor</brief_title>
  <official_title>A Phase Ib, Multicenter, Open-label, Dose-escalation and Dose-expansion Study of the Safety, Tolerability and Pharmacokinetics of HB002.1T in Combination With Chemotherapy in Patients With Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huabo Biopharm Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huabo Biopharm Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic&#xD;
      profile of HB002.1T in combination with different chemotherapy regimens administered to&#xD;
      patients with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase1b, multicenter, open-label, dose-escalation and dose-expansion in&#xD;
      selected solid tumor indications. There are two parts to this study: a dose-escalation part&#xD;
      and a dose-expansion part. About 63-72 subjects is planned to recruit, 27~36 subjects (9~12&#xD;
      subjects each arm) will be recruited during dose-escalation period The sample size may vary&#xD;
      depending on the DLT observed at each dose level. The conventional 3+3 design will be applied&#xD;
      for dose escalation. This trial will evaluate two adaptive dose levels, 3 to 6 subjects will&#xD;
      be enrolled at each dose level depending on the occurrence of dose limiting toxicities&#xD;
      (DLTs). Cohorts of 3 subjects with metastatic or locally advanced solid tumors will receive&#xD;
      HB002.1T at escalating dose levels in combination with different chemotherapy regimens. After&#xD;
      determination of the Maximum tolerated dose (MTD), another 12 patients in each of 3 cohorts&#xD;
      will be added to determine the safety, tolerability, pharmacokinetic (PK), and clinical&#xD;
      activity of HB002.1T.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Maximum Tolerated Dose (MTD) of HB002.1T</measure>
    <time_frame>up to 3 weeks</time_frame>
    <description>Will be determined by dose limiting toxicity. MTD defined as the highest dose level with no more than 1 patient with DLT out of 6 patients that are treated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of HB002.1T</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
    <description>Assessed by Anti-drug Anti-body (ADA) Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>through study completion, up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>HB002.1T + Oxaliplatin+ Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21-24 patients with advanced gastric cancer administeredHB002.1T+ Oxaliplatin+ Capecitabine combination every 3 weeks in a 21-day cycle, total 18cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1T + Paclitaxel + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21-24 patients with advanced ovarian cancer, cervical cancer, head and neck cancer or lung cancer (not limited to the above tumor types) administered HB002.1T + Paclitaxel + Carboplatin combination every 3 weeks in a 21-day cycle, total 18cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HB002.1T + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>21-24 patients with advanced biliary tract tumor, pancreatic cancer, bladder cancer or nasopharyngeal carcinoma (not limited to the above tumor types) administered HB002.1T + Gemcitabine + Cisplatin combination every 3 weeks in a 21-day cycle, total 18cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HB002.1T</intervention_name>
    <description>HB002.1T is a vascular endothelial growth factor receptor decoy</description>
    <arm_group_label>HB002.1T + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>HB002.1T + Oxaliplatin+ Capecitabine</arm_group_label>
    <arm_group_label>HB002.1T + Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin is an anti-tumor drug</description>
    <arm_group_label>HB002.1T + Oxaliplatin+ Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine is an anti-tumor drug</description>
    <arm_group_label>HB002.1T + Oxaliplatin+ Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is an anti-tumor drug</description>
    <arm_group_label>HB002.1T + Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is an anti-tumor drug</description>
    <arm_group_label>HB002.1T + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is an anti-tumor drug</description>
    <arm_group_label>HB002.1T + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is an anti-tumor drug</description>
    <arm_group_label>HB002.1T + Paclitaxel + Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years≤Age≤75 years&#xD;
&#xD;
          2. Histologically or cytologically confirmed advanced malignant solid tumor , including&#xD;
             gastric cancer, ovarian cancer, cervical cancer, head and neck cancer, lung cancer,&#xD;
             biliary tract tumor, pancreatic cancer, bladder cancer and nasopharyngeal carcinoma&#xD;
             (not limited to the above tumor types) . And be suitable for the treatment of HB0021.T&#xD;
             combined with 3 different chemotherapy regimen assessed by the investigators.&#xD;
&#xD;
          3. No prior radiotherapy, chemotherapy, targeted therapy, endocrine therapy or&#xD;
             immunotherapy within 4 weeks before the first administration of HB002.1T. And no&#xD;
             traditional herb medicines for anti-tumor within 2 weeks .&#xD;
&#xD;
          4. No prior antiangiogenic therapy such as bevacizumab, ramucirumab, apatinib or&#xD;
             regofinib, et al.&#xD;
&#xD;
          5. At least one measurable tumor lesion as per RECIST criteria v1.1&#xD;
&#xD;
          6. ECOG performance status of 0 or 1&#xD;
&#xD;
          7. Life expectancy of at least 12 weeks&#xD;
&#xD;
          8. Meet following organ functions:&#xD;
&#xD;
               1. Absolute neutrophil count ≥2.0 x 10^9/L(no Recombinant human granulocyte colony&#xD;
                  stimulating factor support therapy with 14 days)&#xD;
&#xD;
               2. Hemoglobin ≥100g/L(no blood transfusion or erythropoietin support treatment was&#xD;
                  received within 14 days)&#xD;
&#xD;
               3. Platelet count ≥100×10^9/L (No Recombinant human thrombopoietin and other&#xD;
                  supportive therapies within 14 days prior to screening phase)&#xD;
&#xD;
               4. Serum creatinine≤1.5×ULN or creatinine clearance of≥60ml/min (based on the&#xD;
                  Cockcroft Gault formula).&#xD;
&#xD;
               5. Serum total bilirubin≤1.5×ULN.&#xD;
&#xD;
               6. ALT and AST ≤2.5×ULN, with the following exceptions: Patients with liver&#xD;
                  metastases assessed by investigators: AST and/or ALT≤5×ULN&#xD;
&#xD;
               7. Blood potassium≥3.0 mmol/L, blood calcium≥2.0 mmol/L&#xD;
&#xD;
               8. Prothrombin time (PT)≤1.2×ULN, partial prothrombin kinase time (APTT)≤1.2×ULN&#xD;
&#xD;
               9. Urine protein &lt; 1+showed by urine test paper, or urine protein &lt;1g for 24 hours&#xD;
&#xD;
          9. Previous treatment toxicity returned to grade 1 as per NCI CTCAE 5.0, with the&#xD;
             following exceptions :Hair loss or other with no safety risk judged by investigators.&#xD;
&#xD;
         10. Subjects of childbearing potential must be willing to take effective contraceptive&#xD;
             measures throughout the study and for 3 months after the last dose of HB002.1T.And&#xD;
             females must have a negative pregnancy test during the screening period .&#xD;
&#xD;
         11. Ability to understand the patient information and informed consent form and signed and&#xD;
             dated written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who meet any of the following criteria will be excluded from study entry:&#xD;
&#xD;
               1. Confirmed active CNS metastasis and /or cancerous meningitis; For patients with&#xD;
                  stable clinical symptoms for brain metastasis for more than 3months can be&#xD;
                  enrolled.&#xD;
&#xD;
               2. Positive test for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
               3. History of organ transplantationHistory of severe allergy or known severe&#xD;
                  allergic reactions (greater than grade 3 in CTCAE V5.0) to macromolecular protein&#xD;
                  preparations / monoclonal antibodies and any components of the test drug;&#xD;
&#xD;
               4. Have received other clinical trial drugs within 4 weeks before the first&#xD;
                  treatment of HB002.1T;&#xD;
&#xD;
               5. Have undergone major surgery within 4 weeks prior to screening;&#xD;
&#xD;
               6. Have undergone minor surgical procedures (including catheterization, except for&#xD;
                  PICC) within 2 days prior to screening;&#xD;
&#xD;
               7. Systolic blood pressure≥140mmHg and/or diastolic blood pressure≥90mmHg after&#xD;
                  antihypertensive treatment (one antihypertensive drug is allowed in the baseline&#xD;
                  period, and the compound preparation is recognized as two);&#xD;
&#xD;
               8. An active infection requiring antibiotics treatment during the screening period,&#xD;
                  or an unexplained fever &gt; 38.5 °C occurs before the first dose;&#xD;
&#xD;
               9. Hemoptysis within 4 weeks before screening (defined as coughing with ≥1 teaspoon&#xD;
                  of blood), but do not rule out cough only with sputum or small blood clot;&#xD;
&#xD;
              10. Suffering from the following serious complications:&#xD;
&#xD;
                    1. Prior arterial thromboembolic events, venous thrombosis great than grade 3&#xD;
                       or higher in NCI CTCAE5.0&#xD;
&#xD;
                    2. Previous or current persistent bleeding or coagulation disorders&#xD;
&#xD;
                    3. Dominant jaundice and/or coagulopathy caused by abnormal liver function&#xD;
&#xD;
                    4. Chronic Obstructive Pulmonary Disease (COPD) or other respiratory illness&#xD;
                       requiring hospitalization within 4 weeks prior to screening;&#xD;
&#xD;
                    5. History of abdominal hernia, gastrointestinal perforation abscess or acute&#xD;
                       bleeding within 6 months prior to screening;&#xD;
&#xD;
                    6. Esophageal varices, unhealed ulcer, wounds or fractures within 6 months&#xD;
                       prior to screening;&#xD;
&#xD;
                    7. Active cardiovascular diseases including but not limited to transient&#xD;
                       ischemic attack (TIA), cerebral vascular accident (CVA), transmural&#xD;
                       Myocardial infarction), transmural myocardial infarction, myocardial&#xD;
                       infarction (MI), hypertensive crisis or encephalopathy within 6 months prior&#xD;
                       to screening;&#xD;
&#xD;
                    8. Gastrointestinal disorders or conditions that may cause gastrointestinal&#xD;
                       bleeding or perforation (e.g., duodenal ulcer, intestinal obstruction, acute&#xD;
                       Crohn's disease, ulcerative colitis, massive gastrectomy and small bowel&#xD;
                       resection). Patients with chronic Crohn's disease and ulcerative colitis&#xD;
                       (except those with total colectomy and rectal resection) should be excluded&#xD;
                       even in the inactive stage&#xD;
&#xD;
                    9. Patients with hereditary nonpolyposis colorectal cancer or familial&#xD;
                       adenomatous polyposis syndrome;&#xD;
&#xD;
                   10. Previous intestinal perforation and intestinal fistula, still not recover&#xD;
                       after surgical treatment&#xD;
&#xD;
                   11. Absorption of oral drug will be significantly affected assessed by&#xD;
                       investigators (Cohort1 only)&#xD;
&#xD;
              11. Subjects who are in use of warfarin, heparin , aspirin (&gt;325 mg/day) or other&#xD;
                  drugs known to inhibit platelet function within 10 days prior to the first study&#xD;
                  treatment;&#xD;
&#xD;
              12. Subjects receiving dipyridamole, ticlopidine, clopidogrel or cilostazol&#xD;
                  treatment;&#xD;
&#xD;
              13. Subjects with a clear history of neurological or dysfunction, such as poor&#xD;
                  adherence to epilepsy;&#xD;
&#xD;
              14. Pregnant or nursing women;&#xD;
&#xD;
              15. Any other reasons assessed by the investigator that are not suitable for&#xD;
                  participation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai East Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Li, Ph.D</last_name>
    <phone>86-21-38804518</phone>
    <phone_ext>22132</phone_ext>
    <email>tianyoulijin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai East Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Li, Ph.D</last_name>
      <phone>86-21-38804518</phone>
      <phone_ext>22132</phone_ext>
      <email>tianyoulijin@163.com</email>
    </contact>
    <investigator>
      <last_name>Jin Li, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

